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ABSTRACT
A CpG-containing DNA oligonucleotide functional-
ized with the 2-(N-formyl-N-methyl)aminoethyl thio-
phosphate protecting group (CpG ODN fma1555)
was prepared from phosphoramidites 1a–d using
solid-phase techniques. The oligonucleotide beha-
ved as a prodrug by virtue of its conversion to
the well-studied immunomodulatory CpG ODN 1555
through thermolytic cleavage of the 2-(N-formyl-N-
methyl)aminoethyl thiophosphate protecting group.
Such a conversion occurred at 37 C with a half-
time of 73 h. The immunostimulatory properties of
CpG ODN fma1555 were evaluated in two in vivo
assays, one of which consisted of mice challenged
in the ear with live Leishmania major metacyclic
promastigotes. Local intradermal administration of
CpG ODN fma1555 was as effective as that of
CpG ODN 1555 in reducing the size of Leishmania
lesions over time. In a different infectious model,
CpG ODN 1555 prevented the death of Tacaribe-
infected mice (43% survival) when administered
between day 0 and 3 post infection. Administration
of CpG ODN fma1555 three days before infection
resulted in improved immunoprotection (60–70%
survival). Moreover, co-administration of CpG ODN
fma1555 and CpG ODN 1555 in this model increa-
sed the window for therapeutic treatment against
Tacaribe virus infection, and thus supports the use
of thermolytic oligonucleotides as prodrugs in the
effective treatment of infectious diseases.
INTRODUCTION
Over the last few years, our research efforts have focused
on the design and development of thermolytic groups for
50-hydroxyl (1) and phosphate (2–7) protection in an attempt
to implement a ‘heat-driven’ process (8) for the synthesis of
DNA oligonucleotides on microarrays. In sharp contrast to
the current methods employed for oligonucleotide synthesis,
such a process would involve rapid and efﬁcient thermal
removal of protecting groups from oligonucleotides under
neutral conditions throughout chain assembly and ﬁnal depro-
tection. Speciﬁcally, heat-sensitive phosphate/thiophosphate
protecting groups exhibiting unique thermolytic properties
have been incorporated into oligonucleotides via phosphor-
amidites 1–6 (Scheme 1) employing solid-phase techniques.
The deprotection mechanism of each thermolytic phosphate
protecting group is consistent with a well-studied intramole-
cular cyclodeesteriﬁcation reaction (9–12), which has also
been observed by others (13–16). Given the relatively rapid
phosphate deprotection kinetics of DNA oligonucleotides that
have been prepared using phosphoramidites 4, 5 and 6 (6,7),
the thermolytic 3-(2-pyridyl)-1-propyl, 2-[N-methyl-N-
(2-pyridyl)]aminoethyl, and 4-methythio-1-butyl groups for
phosphate protection may indeed ﬁnd application in the
synthesis of oligonucleotides on microarrays considering
the mildness of the deprotection conditions used for each
group. However, oligonucleotides functionalized with the
2-(N-formyl-N-methyl)aminoethyl group for phosphate/
thiophosphate protection require a much higher temperature
(90 C) over a considerably longer period of time ( 3h )t o
complete the thermolytic cleavage of this protecting group.
Although these conditions are not optimal for the preparation
of diagnostic oligonucleotide microarrays, oligonucleotides
functionalized with the 2-(N-formyl-N-methyl)aminoethyl
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doi:10.1093/nar/gki657phosphate/thiophosphate protecting group may serve as
potential therapeutic oligonucleotide prodrugs in vivo on the
basis of the anticipated sluggish removal of the phosphate/
thiophosphate protecting group at 37 C.
Oligonucleotide prodrugs have been the focus of intense
scrutiny in recent years in an effort to facilitate cellular uptake
of antisense oligonucleotides and provide these biomolecules
with increased resistance to hydrolytic nucleases. Thus, mask-
ing the phosphodiester groups of oligonucleotides with acyl-
thioethyl (17–21), acyloxymethyl (22) and 4-acyloxybenzyl
(23,24) protecting groups or with groups derived from
bis(hydroxymethyl)-1,3-dicarbonyl compounds (25,26) that
would expectedly be cleaved upon reaction with intracellular
enzymes, offers a viable solution to the notoriously poor
cellular delivery of negatively charged oligonucleotide drugs.
From this perspective, oligonucleoside phosphorothioates
functionalized with the 2-(N-formyl-N-methyl)aminoethyl
group for thiophosphate protection are likely to exhibit the
characteristics of oligonucleotide prodrugs in that they are
uncharged and, thus, inherently resistant to the hydrolytic
activity of nucleases. A distinctive feature of this class of
modiﬁed oligonucleotides lies in that esterases or other intra-
cellular enzymes are not required for prodrug to drug conver-
sion. Only a 37 C environment is necessary to thermolytically
convert oligonucleoside 2-(N-formyl-N-methyl)aminoethyl
phosphorothioate triesters to functional oligonucleoside
phosphorothioate diesters.
Synthetic single-stranded DNA oligonucleoside phosphoro-
thioates containing unmethylated CpG motifs (CpG ODNs)
have been selected as a model to evaluate whether thermo-
lytic CpG ODNs can be administered as prodrugs in vivo.
Typically, CpG ODNs are rapidly internalized by immune
cells (B cells, macrophages, dendritic cells and monocytes)
(27,28) and localize to endocytic vesicles where they inter-
act with Toll-like receptor 9. This interaction triggers an
immunostimulatory cascade that is characterized by B-cell
proliferation, dendritic cell maturation, natural killer cell
activation, and the secretion of a variety of cytokines, chemo-
kines and polyreactive immunoglobulins (27,29). Such a
pro-inﬂammatory and Th1-biased immune response improves
resistance of the host to infectious pathogenic microorgan-
isms. In this regard, numerous studies indicate that adminis-
tration of CpG ODNs can act alone to improve the response
to parasitic, bacterial and viral infections in animal models
(30–32). In this study, we report the synthesis and character-
ization of a CpG ODN functionalized with thermolytic 2-(N-
formyl-N-methyl)aminoethyl phosphorothioate triesters and
assess for the ﬁrst time its immunostimulatory and immuno-
protective properties in vivo.
MATERIALS AND METHODS
2-(N-Formyl-N-methyl)aminoethan-1-ol (7)
This compound (Scheme 2) was prepared from the reaction
of 2-(methylamino)ethanol (Aldrich) with ethyl formate
(Aldrich) as described earlier (2).
Scheme 1. Deoxyribonucleoside phosphoramidites functionalized with
thermolytic groups for phosphorus protection.
Scheme 2. Synthesis of the phosphinylating reagent 8 and preparation
of deoxyribonucleoside phosphoramidites (1a–d) from suitably protected
deoxyribonucleosides (9a–d). (i) bis(N,N-diisopropylamino)chlorophosphine,
N,N-diisopropylethylamine, CH2Cl2,2 5  C, 2 h; (ii) 8,1 H-tetrazole, MeCN,
25 C, 2–16 h; (iii) silica gel chromatography.
Nucleic Acids Research, 2005, Vol. 33, No. 11 3551N,N,N0,N0-Tetraisopropyl-O-2-[(N-formyl-N-
methyl)aminoethyl]phosphorodiamidite (8)
This phosphinylating reagent (Scheme 2) was prepared
following a procedure that had been modiﬁed from its
earlier version (2,12). To a stirred solution of 2-(N-formyl-
N-methyl)aminoethan-1-ol (3.50 g, 34.0 mmol) and N,N-
diisopropylethylamine (35.0 ml, 201 mmol) in anhydrous
dichloromethane (20 ml) was added, at 25 C, a solution of
bis(N,N-diisopropylamino)chlorophosphine (Aldrich) (9.98 g,
37.4 mmol) in dry dichloromethane (10 ml). Formation
of the phosphorodiamidite was monitored by
31PN M R
spectroscopy, which revealed over a period of 2 h, complete
conversion of bis(N,N-diisopropylamino)chlorophosphine
(dP 135.5 p.p.m.) to the desired product as a mixture of rot-
amers(dP 118.0 and 118.7 p.p.m.).Thesuspension was ﬁltered
and the ﬁltrate was evaporated to an oil under reduced pres-
sure. The material was transferred to a 50 ml round bottom
ﬂask, which was then connected to a vacuum-jacketed short
path distilling head and a distributing adapter. Vacuum
distillation was performed using a heat gun to enable rapid
heating without substantial decomposition. A colorless distil-
late (bp 145 C at 1 mmHg) was obtained in 67% yield (7.58 g,
22.8 mmol).
1H NMR (300 MHz, C6D6): d 3.56 (m, 2H),
3.53 (sept, J = 6.9 Hz, 2H), 3.49 (sept, J = 6.9 Hz, 2H),
2.30 (m, 2H), 1.80 (s, 3H), 1.63 (m, 4H), 1.23 (d, J = 6.9 Hz,
12H), 1.19 (d, J = 6.9 Hz, 12H).
13C NMR (75 MHz, C6D6): d
15.2, 24.0, 24.1, 24.7, 24.8, 26.2, 31.1 (d, JPC = 9.6 Hz), 34.2,
44.6, 44.7, 64.1 (d,
2JPC = 21.5 Hz).
31P NMR (121 MHz,
C6D6): d 118.0, 118.7. EI-HRMS: calcd for C16H36N3O2P
(M )
+ 333.2545, found 333.2528.
General procedure for the preparation of
deoxyribonucleoside phosphoramidites 1a–d
A properly protected deoxyribonucleoside (9a–d, 2 mmol)
was dried under high vacuum for 4 h in a 50 ml round-
bottom ﬂask and, then, dissolved in anhydrous MeCN
(10 ml). To this solution was added N,N,N0,N0-tetraisopropyl-
O-2-[(N-formyl-N-methyl)aminoethyl]phosphorodiamidite
(8, 730 mg, 2.2 mmol) followed by 0.45 M 1H-tetrazole
in MeCN (4.4 ml, 2 mmol), dropwise, over a period of
0.5 h (Scheme 2). Phosphinylation of suitably protected
20-deoxyribonucleosides was usually complete within 2 h at
25 C with the exception of protected 20-deoxyguanosine,
which was allowed to proceed overnight. The reaction mixture
was then concentrated under reduced pressure, dissolved in
benzene:triethylamine (9:1 v/v), and chromatographed using a
column (4 · 10 cm) containing silica gel 60 (230–400 mesh,
 20 g) equilibrated in benzene:triethylamine (9:1 v/v). The
phosphoramidites were eluted from the column using the
equilibration solvent as the eluant. Appropriate fractions were
pooled, concentrated, and each of the deoxyribonucleoside
phosphoramidites 1a–d was obtained as a white foamy mater-
ial. The puriﬁed product was dissolved in  3 ml of benzene
and the solution was added to  100 ml of cold ( 20 C)
vigorously stirred hexane. The suspension was allowed to
settle and most of the supernatant was carefully decanted. The
wet material was pulverized under reduced pressure, and then
dissolved in  10 ml of benzene. The solution was frozen in
a dry-ice/acetone bath, and lyophilized under high vacuum
affording triethylamine-free phosphoramidites as white
amorphous solids in yields ranging from 70 to 85%.
50-O-(4,40-dimethoxytrityl)-30-O-(N,N-diisopropylamino)[2-
(N-formyl-N-methyl)aminoethoxy]phosphinyl-20-deoxy-
thymidine (1a).
31P NMR (121 MHz, C6D6): d 148.4, 148.3,
148.2. FAB-HRMS: calcd for C41H53N4O9P( M + Cs)
+
909.2604, found 909.2544.
N
4-benzoyl-50-O-(4,40-dimethoxytrityl)-30-O-(N,N-diisopro-
pylamino)[2-(N-formyl-N-methyl)aminoethoxy]phosphinyl-
20-deoxycytidine (1b).
31P NMR (121 MHz, C6D6): d 149.0,
148.9, 148.5, 148.4. FAB-HRMS: calcd for C47H56N5O9P
(M + Na)
+ 888.3714, found 888.3745.
N
6-benzoyl-50-O-(4,40-dimethoxytrityl)-30-O-(N,N-diisopro-
pylamino)[2-(N-formyl-N-methyl)aminoethoxy]phosphinyl-
20-deoxyadenosine (1c).
31P NMR (121 MHz, C6D6): d 148.9,
148.8, 148.1. FAB-HRMS: calcd for C48H56N7O8P(M+ Na)
+
912.3827, found 912.3843.
N
2-isobutyryl-50-O-(4,40-dimethoxytrityl)-30-O-(N,N-diiso-
propylamino)[2-(N-formyl-N-methyl)aminoethoxy] phosphi-
nyl-20-deoxyguanosine (1d).
31P NMR (121 MHz, C6D6):
d 149.0, 143.9, 143.7. FAB-HRMS: calcd for C45H58N7O9P
(M + Na)
+ is 894.3933, found 894.3978.
Proton-decoupled
31P NMR spectra were recorded at 7.05 T
(300 MHz for
1H) using deuterated solvents and 85% phos-
phoric acid in deuterium oxide as an external reference. The
NMR spectrometer was run at 25 C and chemical shifts d are
reported in parts per million.
Low- and high-resolution FAB mass spectra were acquired
from samples dissolved in either 4-nitrobenzyl alcohol or a
mixture of dithiothreitol and dithioerythritol (3:1, v/v), and
bombarded with 8 keV fast cesium ions. A mass calibration
standard of cesium iodide, or a mixture of cesium iodide and
sodium iodide, was used. Accurate mass measurements were
performed on [M + H]
+ or on [M + Na]
+ ions, which were
obtained by addition of aqueous sodium iodide to the sample
matrix.
Solid-phase oligonucleotide synthesis
Solid phase synthesis of d(GPS(FMA)CPS(FMA)TPS(FMA)-
APS(FMA)GPS(FMA)APS(FMA)CPS(FMA)GPS(FMA)TPS(FMA)TPS(FMA)-
APS(FMA)GPS(FMA)CPS(FMA)GPS(FMA)T) [CpG ODN fma1555],
d(GPS(FMA)CPS(FMA)TPS(FMA)APS(FMA)GPS(FMA)APS(FMA)-
GPS(FMA)GPS(FMA)TPS(FMA)TPS(FMA)APS(FMA)GPS(FMA)GPS(FMA)-
GPS(FMA)T) [ODN fma1556], where PS(FMA) stands for
a thermolytic 2-(N-formyl-N-methyl)aminoethyl phosphoro-
thioate triester function, and d(GPSCPSTPSAPSGPSAPSCPS
GPSTPSTPSAPSGPSCPSGPST) [CpG ODN 1555], where PS
stands for a phosphorothioate diester function, was performed
on a scale of 1 mmol using a succinyl long chain alkylamine
controlled-pore glass (Succ-LCAA-CPG) support func-
tionalized with 50-O-DMTr-dT as the leader nucleoside.
The syntheses were carried out using an ABI 392 DNA/
RNA synthesizer and phosphoramidites 1a–d or commercial
2-cyanoethyl deoxyribonucleoside phosphoramidites as 0.1 M
solutions in dry MeCN. The reaction time for each phosphor-
amidite coupling step was 180 s. With the exception of the
deblocking solution, all ancillary reagents necessary for the
3552 Nucleic Acids Research, 2005, Vol. 33, No. 11preparation of oligonucleotides were purchased and utilized as
recommended by the instrument’s manufacturer. Given that
only thioated oligodeoxyribonucleotides were prepared, the
iodine oxidation step of the synthesis cycle was replaced
with a sulfurization step employing 0.05 M 3H-1,2-benzo-
dithiol-3-one 1,1-dioxide in MeCN, as recommended in the
literature (33,34). The sulfurization step was performed before
the capping step, and the reaction time for these steps was 120
and 60 s, respectively. The dedimethoxytritylation step of the
synthesis cycle was effected over a period of 60 s with a
freshly prepared solution of 3% trichloroacetic acid (w/v) in
dichloromethane.
Oligonucleotide deprotection and purification
The synthesis column containing the 50-O-dimethoxytritylated
oligonucleotide was placed into a stainless steel pressure ves-
sel and exposed to pressurized ammonia (10 bar at 25  C) for
12 h (35). Upon removal of residual ammonia from the pres-
sure container, the 50-O-DMTr-oligonucleotide was eluted off
the column with 40% MeCN in 0.1 M triethylammonium
acetate (TEAA, pH 7.0) (1 ml). The puriﬁcation of each
oligonucleotide was accomplished by reverse phase high per-
formance liquid chromatography (RP-HPLC) employing a
UV detection system and a semi-preparative 5 mm Supelcosil
LC-18-S column (10 mm · 25 cm). An elution gradient for
the puriﬁcation of 50-O-DMTr-CpG ODN fma1555 or 50-O-
DMTr-ODN fma1556 was optimized as follows: starting from
5% MeCN in 0.1 M TEAA (pH 7.0), 1.5% MeCN/min was
pumped at a ﬂow rate of 3 ml/min for 30 min. A different
elution gradient was however used for the puriﬁcation of 50-O-
DMTr-CpG ODN 1555; thus starting from 0.1 M TEAA
(pH 7.0), 1% MeCN/min was pumped at a ﬂow rate of 3 ml/
min for 40 min. The product peaks were collected and the
eluates were evaporated using a stream of air without heating.
The residue was dissolved in 80% acetic acid (1 ml) and
the solution was left standing at ambient temperature for
30 min. The acidic solution was also evaporated through
the use of a stream of air without a heat source. Each oligo-
nucleotide was then dissolved in a solution of 40% MeCN
in 0.1 M TEAA (pH 7.0) (1 ml) and puriﬁed by RP-HPLC
using the same conditions (column and elution gradient) as
those employed for the puriﬁcation of the respective 50-O-
DMTr-CpG ODN fma1555, 50-O-DMTr-ODN fma1556 and
50-O-DMTr-CpG ODN 1555. The pooling and evaporation of
eluates containing each puriﬁed 50-O-deprotected oligonuc-
leotide was performed in a manner similar to that described
for the respective 50-O-DMTr-oligonucleotides. After recon-
stitution of each puriﬁed oligonucleotide in ddH2O (1 ml), its
concentration was determined by UV spectrophotometry at
260 nm. The recovered yields of CpG ODN fma1555 and
ODN fma1556 were 65 and 68 OD260 units, respectively,
whereas the recovered yield of CPG ODN 1555 was 95
OD260 units. Each oligonucleotide solution was stored frozen
at  20 C.
Oligonucleotide characterization
RP-HPLC analysis of puriﬁed CpG ODN fma1555 was per-
formed using an analytical 5 mm Supelcosil LC-18S column
(4.6 mm · 25 cm) according to the following conditions:
starting from 0.1 M TEAA (pH 7.0), a linear gradient of
1% MeCN/min was pumped at a ﬂow rate of 1 ml/min for
40 min. An RP-HPLC proﬁle of the puriﬁed oligonucleotide
is shown in Figure 1.
Samples of puriﬁed CpG ODN fma1555, CpG ODN 1555
and ODN 1556 were analyzed employing a Waters 1525m
binary pump equipped with a Waters 2777 sample manager,
which was connected online to an orthogonal Electrospray
Ionization Time of Flight (ESI-TOF) mass spectrometer
(Micromass LCT Premier, Waters, Milford, ME). The mobile
phase for direct introduction of the sample was composed of
0.2% formic acid (40%) and acetonitrile (60%). MS chroma-
tograms were acquired in the positive ion mode using an
ESI-MS capillary voltage of 3.5 kV, a sample cone voltage
of 60 V, and an MCP detector voltage of 2200 V. Desolvation
gas ﬂow rate was maintained at 400 l/h, cone gas ﬂow rate at
50 l/h. Desolvation temperature and source temperature were
set to 150 and 80 C, respectively. The acquisition range was
set at m/z 50–2000. The 2.1 s scan cycle consisted of a 2 s
acquisition time and a 0.1 s interscan delay. Instrument cal-
ibration was performed routinely in positive ion mode prior
to MS experiments by direct infusion of sodium formate in 2-
propanol:water (9:1 v/v) at 10 ml/min. Leu-enkephalin was
used as a lock mass and MassLynx was the operating software
for the MS system. Raw summed spectra were deconvoluted
using the MaxEnt1  software.
To further characterize CpG ODN fma1555 and ODN
fma1556, the puriﬁed oligonucleotides (1 OD260 unit each)
were dissolved in 1· Phosphate-buffered saline (PBS, pH 7.2)
(0.5 ml) and placed in a heat block, pre-heated to 37 – 2 C, to
thermolytically cleave the 2-(N-formyl-N-methyl)aminoethyl
thiophosphate protecting group over a period of 626 h. Each
fully deprotected oligonucleotide (0.25 OD260 unit) was ana-
lyzed by PAGE using a denaturing 20% polyacrylamide–7 M
urea gel (40 cm · 20 cm · 0.75 mm), which was prepared as
described by Maniatis et al. (36). Electrophoresis was carried
out at 350 V until the bromophenol blue dye of the loading
buffertraveled  80%of the lengthof the gel. The gel was then
stained by soaking in a solution of Stains-all, as reported
elsewhere (10). A photograph of the gel is shown in Figure 2.
Figure1.RP-HPLCprofilesofd(GPS(FMA)CPS(FMA)TPS(FMA)APS(FMA)GPS(FMA)-
APS(FMA)CPS(FMA)GPS(FMA)TPS(FMATPS(FMA)APS(FMA)GPS(FMA)CPS(FMA)-
GPS(FMA)T) [CpG ODN fma1555]. Magenta line: Chromatographic profile of
purified CpG ODN fma1555. Brown line: Chromatographic profile of purified
CpG ODN fma1555 that was heated in 1· PBS (pH 7.2) for 626 h at 37 C.
Turquoise line: Chromatographic profile of purified CpG ODN fma1555 that
was heated in 1· PBS (pH 7.2) at 37 C for 73 h. RP-HPLC analyses were
performed using a 5 mm Supelcosil LC-18Scolumn(4.6 mm · 25 cm) accord-
ing to the following conditions: starting from 0.1 M TEAA (pH 7.0), a linear
gradientof1%MeCN/minispumpedataflowrateof1ml/minfor40min.Peak
heights of each profile are normalized to the highest peak, which is set to one
arbitrary unit.
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fma1556 were assayed for endotoxins using the Limulus
amebocyte lysate assay and were found to contain <0.1 endo-
toxin unit per mg of oligonucleotide.
Virus and growth conditions
Tacaribe virus (TCRV strain TRVL 11573) was obtained
from American Type Culture Collection (ATCC VR-114,
Manassas, VA) as a suckling mouse brain desiccate and
expanded in Vero cell monolayers in P75 cell culture ﬂasks
(Corning) for eight days at 37 C in R5 or R10 medium
(RPMI 1640, 5 or 10% heat-inactivated fetal calf serum,
1.5 mM L-glutamine, 100 U penicillin/ml and 100 mgo f
streptomycin/ml) (Invitrogen) as described (37). Cell-free
supernatant was harvested, aliquoted and frozen at  70 C
for use in mouse infections. TCRV titers were determined
using the Tissue culture ID50 method (38). Brieﬂy, the
virus-containing suspension was diluted (10
 1 to 10
 11)i n
R5 medium in a 96-well round-bottom plate (Costar). Trip-
licate to quadruplicate dilutions were subsequently overlaid on
Vero cell monolayers cultured in a 96-well ﬂat-bottom plate
(Costar). The virus was allowed to adhere 1–2 h at 37 C
whereupon the virus suspension was removed from the
plate and fresh R5 medium added. Cells were monitored
daily for the development of cytopathic effects and were
scored after 6–8 days of incubation at 37 C. The virus titer
was deﬁned as the last dilution showing mild cytopathic
effects in culture in two out of three replicate wells. A similar
method was used to titer viruses in tissue homogenates made
from infected neonatal brains (38).
Animals and infection protocols
Balb/C mice were obtained from the National Cancer Institute
(Frederick, MD), housed in sterile microisolator cages in
the CBER-speciﬁc pathogen-free animal facility, and bred
at 6–12 weeks of age. All experiments were approved by
the FDA Animal Care and Use Committee.
Protocol A. To assess immune activation in vivo, healthy 1–3
month old female Balb/C mice were administered CpG ODN
1555 or fma1555 intraperitoneally (IP). Control mice received
saline. For experiments assessing the kinetics of immune
activation, spleen cells were collected 24, 72 and 120 h
after treatment and the number of cytokine-secreting cells
enumerated by ELIspot as previously described (39). For
studies addressing dose response, spleens were harvested
72 h after treatment with CpG ODN 1555 or fma1555 (30,
100 or 300 mg/mouse, IP). Control mice received saline or
ODN fma1556 (100 mg/mouse). Brieﬂy, four dilutions of sin-
glecellsuspensionswereoverlaidon96-wellImmunolonH2B
plates coated with antibodies to IL-12, IL-6 (BD Pharmingen,
San Diego, CA), TNFa (R&D systems, Minneapolis, MN) or
anti-IgM (Southern Biotechnology Associates, Birmingham
AL). After 5 h at 37 C, the cells were washed away and
overlaid with biotin-conjugated antibodies to IL-12, IL-6
(BD Pharmingen), TNF-a (Genzyme, Cambridge, MA) or
IgM (Southern Biotechnology Associates) followed by
phosphatase-conjugated avidin (BD Pharmingen). After a
ﬁnal wash, spots were visualized by the addition of 5-
bromo-4-chloro-3-indolyl phosphate (Kirkegaard and Perry
Laboratories, Gaithersburg, MD) in low melt agarose
(Sigma, St Louis, MO). Spots generated by individual
cytokine secreting cells were counted manually using a 40·
magniﬁcation and are expressed as per 10
6 spleen cells.
Protocol B. Infections with Leishmania major were performed
as described (40). L.major clone VI (MHOM/IL/80/Friedlin)
Promastigotes (kindly provided by Sylvie Bertholet) were
grown at 26 C in medium 199 supplemented with 20% Hi-
FCE (HyClone), 100 U penicillin/ml, 100 mg of streptomycin/
ml, 2 mM L-glutamine, 40 mM HEPES, 0.1 mM adenine in
50mM HEPES, 5mg of hemin/mlof 50% triethanolamine and
1 mg of 6-biotin (M199/S)/ml. Infective-stage (metacyclic)
promastigotes of L.major were isolated from stationary cul-
tures (4- to 5-days old) by negative selection of infective forms
using peanut agglutinin (Vector Laboratories). Three groups
of Balb/c mice (6–10 weeks of age, four mice per group) were
infected in the ear dermis with 1000 metacyclic promastigotes
using a 27.5-gauge needle in a total volume of 5 ml. Each of
two groups of animals was treated intradermally at the site
with 25 mg of CpG ODN fma1555 or CpG ODN 1555. The
third group was left untreated. The number of parasites and
total volume was maintained constant for all animals. Cuta-
neousinoculationoflivemetacyclicL.majorparasitescausesa
cutaneous lesion that models those observed in human cuta-
neous leishmaniasis. The size of the lesion was monitored
weekly. Statistical analysis was performed by one-way
ANOVA (analysis of variance) using the SigmaStat software.
The Student–Newman–Keuls test was selected to determine
the null hypothesis probability values.
Protocol C. Neonatal BALB/c mice were bred in-house
under speciﬁc pathogen-free conditions. Newborn mice were
Figure 2. PAGE analysis of fully deprotected and RP-HPLC-purified
oligonucleoside phosphorothioates under denaturing conditions (20%
polyacrylamide–7 M urea, 1· TBE buffer, pH 8.3). Left lane: CpG ODN
1555 synthesized from commercial 2-cyanoethyl deoxyribonucleoside phos-
phoramidites and deprotected by treatment with pressurized ammonia gas
( 10 bar) for 12 h at 25 C. Middle lane: CpG ODN fma1555 synthesized
from phosphoramidites 1a–d and deprotected by treatment with pressurized
ammoniagas( 10bar)for12hat25 Cfollowedbyheatingin1·PBS(pH7.2)
for 626 h at 37 C. Right lane: ODN fma1556 synthesized and deprotected
under conditions identical to those used for CpG ODN fma1555. Oligonucleo-
tides are visualized as purple bands upon staining the gel with Stains-all.
Bromophenol blue is used as a marker and shows as a large band, in each lane,
at the bottom of the gel.
3554 Nucleic Acids Research, 2005, Vol. 33, No. 11infected intraperitoneally with TCRV (2000 TC50/animal)
1–4 days after birth. Mice were treated with CpG ODN
fma1555 or CpG ODN 1555 (50 mg/mouse) on the day of
infection (n = 9 for each group of mice) or three days before
infection (n = 8 or 7, respectively, for each group of mice).
Mice were also treated with a combination of CpG ODN
fma1555 (25 mg/mouse) and CpG ODN 1555 (25 mg/mouse)
on the day of infection (n = 11) or three days before infection
(n = 10). Mice that were left untreated (n = 11) or received an
ODN lacking a CpG motif (ODN fma1556, 50 mg/mouse,
n = 6) three days before the infection were used as negative
controls. The mice were monitored daily but infections were
allowed to proceed to their natural outcome in order to assess
survival. For each condition, survival was determined from
2 to 4 independent experiments using 2–4 mice per group
in each experiment. No obvious delay in development or
weight loss was observed in uninfected mice treated with
the oligonucleotides.
RESULTS AND DISCUSSION
The preparation of the deoxyribonucleoside phosphoramidites
1a–d is a prerequisite to solid-phase synthesis of oligonuc-
leotides functionalized with the thermolytic 2-(N-formyl-N-
methyl)aminoethyl thiophosphate protecting group. These
phosphoramidites are obtained from the reaction of suitably
protected deoxyribonucleosides (9a–d) with the phosphorodi-
amidite 8 and 1H-tetrazole (Scheme 2) essentially as reported
by Lee and Moon (41). The crude phosphoramidites are puri-
ﬁed by silica gel chromatography using an eluant containing
triethylamine to prevent dedimethoxytritylation and hydro-
lysis of the phosphoramidite monomers during puriﬁcation
given the inherent acidity of silica gel. It is therefore critic-
ally important to remove excess triethylamine from the
puriﬁed phosphoramidites monomers to avoid neutralization
of 1H-tetrazole and poor coupling efﬁciency during solid-
phase oligonucleotide synthesis. The removal of residual
triethylamine from puriﬁed 1a–d is preferably achieved by
dissolving the phosphoramidites in a minimum amount of
dry benzene followed by precipitation in a large volume of
cold hexane. To ensure complete removal of triethylamine and
adventitious moisture, the phosphoramidite precipitate is dis-
solved in a substantial amount of dry benzene ( 10 ml/g)
and then freeze-dried under high vacuum over an extended
period of time (16–24 h).
Characterizationof the phosphoramidites 1a–d by
31PNMR
spectroscopy revealed a noteworthy multiplicity of signals at
25 C. Typically, four signals are observed for 1b and three
signals each for 1a, 1c and 1d. However, only two broad
31P
NMR signals are seen when either 1b or 1c is heated to 50 C
in the NMR probe. These observations are consistent with
the notion of 1a–d existing as a mixture of diastereomeric
rotamers (Scheme 2) as a consequence of the partial double-
bond character of the C–N bond in tertiary amides (11). Like-
wise, the achiral phosphinylating reagent 8 also exists as a
mixture of two rotamers as evidenced by two
31P NMR signals
observed at dP 118.0 and 118.7 p.p.m.
The puriﬁed deoxyribonucleoside phosphoramidites 1a–d
are used as 0.1 M solutions in anhydrous MeCN in the
solid-phase synthesis of CpG ODN fma1555 and ODN
fma1556 according to a modiﬁed synthesis cycle. Commercial
2-cyanoethyl deoxyribonucleoside phosphoramidites are also
employed under identical conditions in the preparation of
CpG ODN 1555, which serves as a positive immunostimulat-
ory control oligonucleotide in mice. Modiﬁcations of the
standard solid-phase oligonucleotide synthesis cycle include:
(i) extending the phosphoramidite coupling time to 180 s;
(ii) replacing the iodine oxidation step with a sulfurization
step effected by 0.05 M 3H-1,2-benzodithiol-3-one 1,1-
dioxide in MeCN over a period of 120 s; (iii) performing
the sulfurization step before the capping step to minimize
phosphorus oxygenation (33) and (iv) extending the capping
reaction time to 60 s to ensure efﬁcient chain termination of
shorter than full-length oligonucleotides.
Upon completion of the last synthesis cycle, the terminal
50-O-DMTr group is not removed from the oligonucleotide
to facilitate its hydrophobic separation from a population of
shorter 50-O-acetylated oligonucleotides that failed quantitat-
ive chain extension during oligonucleotide synthesis. The
solid support is exposed to pressurized ammonia gas to cleave
nucleobase protecting groups and release the oligonucleotide
from the support. It is important to note that in the case of
CpG ODN fma1555 and ODN fma1556, the standard
conditions used for nucleobase deprotection (concentrated
NH4OH, 55 C, 10 h) were unsatisfactory, as these caused
unwanted thermolytic cleavage of the 2-(N-formyl-N-
methyl)aminoethyl thiophosphate protecting group to an
unacceptable level and resulted in an intractable mixture of
oligonucleotides.
The 50-O-DMTr-oligonucleotide is eluted off the column
along with the shorter oligonucleotides, and is puriﬁed by
RP-HPLC using a column packed with a C18 resin, which
has a higher afﬁnity for the 50-O-DMTr-oligonucleotide
thanforthe shorter50-O-acetylatedoligonucleotides. Thepuri-
ﬁed 50-O-DMTr-DNA oligonucleotide is then dedimethoxy-
tritylated upon treatment with 80% acetic acid and re-puriﬁed
by RP-HPLC through a C18 column. The chromatographic
proﬁle of CpG ODN fma1555 is shown in Figure 1 and exhib-
its a retention time (tR) of 37 min. The shape of the peak
corresponding to the puriﬁed oligonucleotide is consistent
with that of a complex mixture of rotameric diastereomers (2).
Characterization of the puriﬁed CpG ODN fma1555,
CpG ODN 1555 and ODN fma1556 by mass spectrometry
resulted in the following mass determinations: CpG ODN
fma1555 (+ESI-TOF MS): calcd for C203H283N71O89P14S14
(M)
+ 6024, found 6023. ODN fma1556 (+ESI-TOF MS):
calcd for C205H283N75O89P14S14 (M)
+ 6105, found 6103.
CpG ODN 1555 (+ESI-TOF MS): calcd for C147H185N57
O75P14S14 (M + 14H)
+ 4832, found 4832. The experimental
mass determination of each oligonucleotide is in close agree-
ment with its expected mass, and thus conﬁrms its identity.
A kinetic proﬁle of the thermolytic cleavage of the 2-(N-
formyl-N methyl)aminoethyl thiophosphate protecting group
is obtained by heating puriﬁed CpG ODN fma1555 and ODN
fma1556 to 37 or 90 Ci n1 · PBS (pH 7.2), and analyzing the
deprotection reaction at various time points by RP-HPLC. The
half-time of thiophosphate deprotection is estimated to be 73 h
at 37 C, and complete deprotection is achieved within 600 h.
Fully deprotected CpG ODN fma1555 exhibited a tR (23 min)
identical to that of CpG ODN 1555 under identical chroma-
tographic conditions (Figure 1). The thermolytic deprotection
Nucleic Acids Research, 2005, Vol. 33, No. 11 3555mechanism presumably proceeds through a cyclodeesteriﬁca-
tion mechanism (Scheme 3) that is typically observed with
many of the thermosensitive phosphate/thiophosphate protect-
ing groups investigated earlier (2,4,6,7).
PAGE analysis of puriﬁed and fully deprotected CpG ODN
fma1555, ODN fma1556 and CpG ODN 1555 showed that
each oligonucleotide migrated on the gel as a homogeneous
band. A photograph of the stained gel is shown in Figure 2.
Although deprotected CpG ODN 1555 and CpG ODN
fma1555 exhibited an identical electrophoretic mobility indic-
ative of an identical DNA sequence, deprotected ODN 1556
displayed a slightly different mobility. It should be understood
that the electrophoretic mobility of a synthetic oligonucleotide
depends more on its base composition than its length (42).
Since ODN 1556 has a different DNA sequence than that of
CpG ODN 1555, its electrophoretic mobility was expected to
differ from that of CpG ODN 1555 in spite of an identical
chain length.
The immunostimulatory properties of CpG ODN fma1555
were evaluated in vivo in mice and compared with those of
CpG ODN 1555, which were described earlier (43). Prior
studies had shown that treatment with CpG ODNs induced
an increase in the number of cytokine secreting cells (44).
Given that the thermolytic deprotection of CpG ODN
fma1555 proceeds with a half-time of 73 h at 37 C, expression
of its immunoprotective properties should be delayed
relative to that of CpG ODN 1555. As shown in Figure 3,
splenocytes from Balb/c mice treatedwith CpGODNfma1555
had a delayed increase in IL-6 and IL-12 secreting cells when
compared to mice that received CpG ODN 1555. Importantly,
the number of IL-12 secreting cells was still increased 120 h
after treatment, as compared to mice receiving CpG ODN
1555. To assess whether the number of cytokine secreting
cells was dose dependent, mice were treated intraperitoneally
with CpG ODN 1555 or fma1555 (30, 100 or 300 mg/mouse,
3 mice/group) and euthanized 72 h after treatment. As shown
in Figure 4, there is a direct correlation between the dose
Scheme3.Tentativemechanismofthethermolyticcleavageof2-(N-formyl-N-
methyl)aminoethylthiophosphateprotectinggroupsfromCpGODN fma1555.
(i)NH3gas( 10bar),12h,25 C;(ii)0.1MTEAA(pH7.0)or1·PBS(pH7.2),
90 C, 3 h.
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Figure 3. Kinetics of cytokine secretion in mice treated with CpG ODN
fma1555. Female Balb/c mice (6–12 weeks of age, 3–6/group) were adminis-
tered CpG ODN 1555or CpG ODN fma1555(100mg/mouse)intraperitoneally
andtheneuthanized24,72or120hlater.Showninthisgrapharethenumberof
cells secreting IL-6 and IL-12 (p40/p70) ex vivo, as determined by ELIspot for
each time point.
3556 Nucleic Acids Research, 2005, Vol. 33, No. 11of CpG ODN fma1555 and the number of cytokine- and
immunoglobulin-secreting cells in spleen. Mice treated with
ODN fma1556 did not elicit cytokine secretion.
CpG ODNs have been shown to activate the innate immune
system to improve the clinical outcome in several infectious
models. Speciﬁcally, studies assessing the immunoprotect-
ive effects of CpG ODNs show that administration of CpG-
containing DNA oligonucleotides alone (but not control
oligonucleotides lacking CpG motifs) reduces the severity of
an intradermal L.major challenge in mice when administered
asearly as threedays priorto infection or aslate asthree weeks
post infection (45). To assess the immunoprotective properties
of CpG ODN fma1555, adult female Balb/c mice were
challenged with live L.major metacyclic promastigotes
intradermally in the ear and left either untreated or treated
in situ with 25 mg of CpG ODN fma1555 or CpG ODN
1555 (Figure 5). As reported earlier, untreated Balb/c mice
developed an ulcerative skin lesion that ultimately led to the
loss of the outer ear 10 weeks after infection (40). In contrast,
Balb/c mice that were treated with CpG ODN fma1555 or CpG
ODN 1555 showed a signiﬁcant (P < 0.05) reduction in der-
mal pathology by comparison to that of untreated mice, as
assessed by one-way ANOVA. Although the lesions tended to
be smaller in CpG ODN 1555-treated mice than in CpG ODN
Figure 4. DoseresponseinmicetreatedwithCpG ODNfma155572hpostadministration. FemaleBalb/cmice(3–6 mice/group)receivedCpG ODN1555orCpG
ODNfma1555(30,100or300mg/mouse)intraperitoneally.Splenocyteswerecollected72haftertreatment.ShowninthisfigurearethenumbersofcytokineandIgM
secreting cells per 10
6 splenocytes.
Nucleic Acids Research, 2005, Vol. 33, No. 11 3557fma1555-treated mice (Figure 5), the difference was not
statistically signiﬁcant. This study demonstrated that the
thermolytic CpG-ODN fma1555 is biologically active and
can elicit a protective immune response in mice infected
with an intracellular pathogen.
To further assess whether CpG ODN fma1555 behaves as
a prodrug, a model of TCRV infection in neonatal mice was
used. The TCRV is a New World arena virus that causes a
lethal meningoencephalitis in newborn mice. We showed that
treatment with CpG-ODN 1555 (50 mg/mouse) protected 43%
of the newborn mice from death. As shown in several murine
models, the therapeutic window for protection is narrow;
treatment was effective when the oligonucleotides were
administered at the time, or up to three days after TCRV
infection. Mice that received CpG ODN 1555 three days prior
to infection were not protected and died from lethal menin-
goencephalitis at the same rate as untreated mice (Figure 6a).
As shown in Figure 6b, mice treated with CpG ODN fma1555
(50 mg/mouse) at the time of TCRV infection were not pro-
tected from death, but mice that received the treatment three
days before infection had improved survival. The protective
effect of ODN fma1555 was CpG-mediated, as mice treated
with ODN fma1556 lacking CpG motifs were not protected.
These ﬁndings indicate that the 2-(N-formyl-N-methyl)
aminoethyl (fma) thiophosphate protecting group and/or its
thermolytically cleaved counterpart [tentatively, 2-(N-formyl-
N-methyl)aminoethanol] do not impart signiﬁcant immuno-
protective properties to CpG ODNs fma1555. Interestingly,
when CpG ODN fma1555 and CpG ODN 1555 were
co-administered (25 mg of each ODN/mouse) three days
prior to or on the same day of the TCRV challenge, the
survival rate averaged better than 50% (Figure 6c), thereby
suggesting that the combination of CpG ODN 1555 and CpG
ODN fma1555 widened the window of therapeutic treatment
against the disease. Future experiments will be necessary
to determine the mechanism and kinetics of the local
and systemic immunostimulation elicited by CpG ODN
fma1555. However, our results are consistent with the notion
that CpG ODN fma1555 behaves as a prodrug in vivo through
an unprecedented thermolytic process. These ﬁndings thus
pave the way to the development of new thermolytic CpG-
containing oligonucleotide prodrugs exhibiting various half-
time of thiophosphate deprotection to enable the preparation
of more efﬁcient immunotherapeutic oligonucleotide formu-
lations for the treatment of asthma, cancer, autoimmune and
various infectious diseases.
Figure 5. Immunoprotection of mice treated with CpG ODN fma1555 against
progressive L.major infection. Balb/c mice (4 mice/group) were challenged
in the ear with 10
3 live L.major metacyclic promastigotes. The mice were
either left untreated or received a single treatment at the site (ID) with CpG
ODN1555orCpGODNfma1555.Thelesionsizewasmonitoredweekly.Note
the reductionin lesion sizein treated versusuntreatedmice.Statisticalanalysis
was performed by one-way ANOVA (* indicates P < 0.05, ** indicates
P < 0.01). The difference between mice treated with CpG ODN 1555 and
CpG ODN fma1555 was not statistically significant.
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Figure 6. Survival of TCRV-infected mice treated with CpG ODN fma1555. Newborn Balb/c mice (1–4 days old) were infected with TCRV (2000 TC50/mouse).
(a)CpGODN1555(50mg/mouseIP)protectsnewbornmicefrominfectionwhenadministeredatthetimeofinfection(opensquares,n = 9),butcannotprotectmice
if administered three days prior to infection (open triangles, n = 7). (b) CpG ODN fma1555 (50 mg/mouse) administration protected mice when administered three
dayspriortoinfection(opentriangles,n = 8),butnotwhenadministeredatthetimeofinfection(opensquares,n = 9).ControlmicereceivedODNfma1556lacking
CpGmotifsonday 3(opendiamonds,n = 6).(c)CombinationofCpGODN1555(25mg/mouse)andCpGODNfma1555(25mg/mouse)administeredonday 3
(closed triangles, n = 10) or at the time of infection (closed squares, n = 11) extends the period of treatment against the disease.
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